Quick Takeaways
- ACORN BIOVENTURES, L.P. filed SCHEDULE 13G for Candel Therapeutics, Inc. Common stock, par value $0.0001 per share (CADL).
- Disclosed ownership: 5.2%.
- Date of event: 25 Jun 2025.
ACORN BIOVENTURES, L.P. - 25 Jun 2025 SCHEDULE 13G Report for Candel Therapeutics, Inc. Common stock, par value $0.0001 per share (CADL)
- Filing Manager
- ACORN BIOVENTURES, L.P.
- Reporting Manager
- Anders Hove
- Symbol
- CADL
- Shares outstanding
- 49,625,327 shares
- Disclosed Ownership
- 2,580,517 shares
- Ownership
- 5.2%
- Form type
- SCHEDULE 13G
- Filing time
- 30 Jun 2025, 09:55:23 UTC
- Date of event
- 25 Jun 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"ACORN BIOVENTURES, L.P. disclosed 5.2% ownership in Candel Therapeutics, Inc. Common stock, par value $0.0001 per share (CADL) on 25 Jun 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 30 Jun 2025, 09:55.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (5)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| ACORN BIOVENTURES, L.P. | 2.2% | 1,083,818 | 0 | 1,083,818 | Anders Hove | Manager of General Partner | |
| ACORN BIOVENTURES 2, L.P. | 3% | 1,496,699 | 0 | 1,496,699 | Anders Hove | Manager of General Partner | |
| ACORN CAPITAL ADVISORS GP, LLC | 2.2% | 1,083,818 | 0 | 1,083,818 | Anders Hove | Manager | |
| Acorn Capital Advisors GP2, LLC | 3% | 1,496,699 | 0 | 1,496,699 | Anders Hove | Manager | |
| Anders Hove | 5.2% | 2,580,517 | 0 | 2,580,517 | Anders Hove | Individually |